Production (Stage)
Oruka Therapeutics, Inc.
ORKA
$12.58
$0.393.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.16M | 6.00M | 3.76M | 2.82M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.09M | 37.46M | 29.45M | 21.49M | 6.86M |
| Operating Income | -25.09M | -37.46M | -29.45M | -21.49M | -6.86M |
| Income Before Tax | -21.00M | -33.39M | -28.62M | -22.24M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.00M | -33.39M | -28.62M | -22.24M | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.00M | -33.39M | -28.62M | -22.24M | -7.08M |
| EBIT | -25.09M | -37.46M | -29.45M | -21.49M | -6.86M |
| EBITDA | -25.07M | -37.44M | -29.45M | -- | -- |
| EPS Basic | -0.40 | -0.54 | -1.46 | -47.69 | -15.17 |
| Normalized Basic EPS | -0.31 | -0.46 | -1.19 | -29.81 | -- |
| EPS Diluted | -0.40 | -0.54 | -1.46 | -47.69 | -15.17 |
| Normalized Diluted EPS | -0.31 | -0.46 | -1.19 | -29.81 | -- |
| Average Basic Shares Outstanding | 41.68M | 43.86M | 15.01M | 466.40K | -- |
| Average Diluted Shares Outstanding | 41.68M | 43.86M | 15.01M | 466.40K | 466.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |